Gardasil leads the charge as Merck vaccines soar in Q3


With some key meds falling short of expectations in the third quarter, Merck’s ($MRK) vaccines turned in impressive sales to help carry the drug giant to overall growth.

All told, Merck’s vaccines reeled in just over $2 billion in the third quarter, a significant leap--27%--from last year’s $1.59 billion. To get there, the unit saw sizable increases from HPV vaccine Gardasil, pneumococcal vaccine Pneumovax 23 and in MMR/varicella vaccines.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

What accounted for the vaccines growth? For the Gardasil franchise, which expanded sales 38% over the same period last year to $860 million, it was “increased pricing and demand,” as well as the timing of public sector purchases. Gardasil beat analyst estimates by more than $200 million.

Over the period, competitor GlaxoSmithKline ($GSK) pulled a rival HPV vaccine, Cervarix, from the U.S. market due to “very low” demand, handing Merck complete control of that market. Now, the company pharma will be watching closely to see how brand new recommendations from the CDC for a two-dose HPV vaccine schedule will affect sales. Public health officials continue to work to boost lagging U.S. HPV vaccination rates.

Proquad and other MMR/varicella vaccines, which grew 27% over last year’s third quarter to $496 million, also benefited from sales timing relating to pediatric stockpiling. Pneumovax 23 sales jumped 27% to $175 million for the period.

Merck’s strong vaccines performance came as key products elsewhere in its portfolio--notably Keytruda, Januvia and Zepatier--turned in sales lower than analyst expectations.

For the New Jersey-based company, which EvaluatePharma recently predicted to trail other leading players GSK, Sanofi ($SNY) and Pfizer ($PFE) in 2022 vaccine sales, the results come following a Q2 in which it grew sales in the category by just 1%.

But the company could soon see a shakeup in shingles, where its Zostavax grew sales 6% on the quarter to $190 million. Just this week, GSK filed an application with the FDA for its Shingrix, which GSK vaccines head Moncef Slaoui said will be a “major” market disruptor if it’s able to secure approval. Analysts expect to see more than $1 billion in peak sales for that shot.

Related Articles:
GSK exits U.S. market with its HPV vaccine Cervarix
Merck's vax sales fail to see same growth reported by peers
Revved up by Novartis swap, GSK expected to top Sanofi, Pfizer and Merck in 2022 vax sales
CDC aims to jump-start Gardasil uptake with a new two-dose HPV shot schedule
CDC calls on doctors to pitch HPV shots as cancer prevention, not STD protection
Merck holds parents accountable in new Gardasil ad campaign

Suggested Articles

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.